Advanced Filters
noise

immune-thrombocytopenic-purpura Clinical Trials

A listing of immune-thrombocytopenic-purpura medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 90 clinical trials
R Rongfeng Fu, MD

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

18 years of age All Phase 2
S Shuo Chen, MD

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

This multi-center study aims to study the efficacy of TPO-RAs' transformation in Chinese ITP patients older than 14 years. This study will be conducted in ITP patients who had not responded to first-line in the previous treatment .

14 years of age All Phase N/A
S Sanbin Wang, MD

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).

8 - 75 years of age All Phase 1/2
C Chaoke Bu, Doctor

Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia

This study is a clinical study initiated by single-arm, single-center, multiple administration researchers. The main purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells in refractory ITP subjects. The subjects voluntarily signed the informed consent form, and after the evaluation of the screening period …

4 - 75 years of age All Phase N/A
Y Yunfei Chen, MD

Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients

Evaluation of immune status before and after splenectomy in immune thrombocytopenia patients.

18 - 60 years of age All Phase N/A
M Min Yang, MD

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.

18 - 60 years of age All Phase 1
M Ming Hou, PhD

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia

18 - 80 years of age All Phase 3
S Songyi Park

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia

19 years of age All Phase 2
W Wei Qin, doctor

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia. 9 patients are planned to be enrolled in the dose-escalation trial (9×10\^9 cells, 13.5×10\^9 cells). The primary objective of the study is to evaluation …

18 - 65 years of age All Phase 0

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

1 - 18 years of age All Phase N/A

Simplify language using AI